Classification of weakly carcinogenic human papillomavirus types: Addressing the limits of epidemiology at the borderline

被引：343

作者：

Schiffman M. ^{[1
]}

Clifford G. ^{[2
]}

Buonaguro F.M. ^{[3
]}

机构：

[1] Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Bethesda, MD

[2] International Agency for Research on Cancer

[3] Unit of Viral Oncogenesis and Immunotherapy, Istituto Nazionale Tumori Fond G. Pascale, Naples

来源：

Infectious Agents and Cancer | / 4卷 / 1期

关键词：

Cervical Cancer; Genital Wart; Normal Cytology; External Genital Wart; Powerful Carcinogen;

D O I：

10.1186/1750-9378-4-8

中图分类号：

学科分类号：

摘要：

Virtually all cases of cervical cancer are caused by persistent infections with a restricted set of human papillomaviruses (HPV). Some HPV types, like HPV16 and HPV18, are clear and powerful carcinogens. However, the categorization of the most weakly carcinogenic HPV types is extremely challenging. The decisions are important for screening test and vaccine development. This article describes for open discussion an approach recently taken by a World Health Organization International Agency for Research on Cancer (IARC) Monographs Working Group to re-assess the carcinogenicity of different HPV types. © 2009 Schiffman et al.

引用

共 25 条

[1]

Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S., Human papillomavirus and cervical cancer, Lancet, 370, 9590, pp. 890-907, (2007)

[2]

Castle P., The Evolving Definition of Carcinogenic Human Papillomavirus Infectious, Agents and Cancer, (2009)

[3]

Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., Benbrahim-Tallaa L., Guha N., Freeman C., Galichet L., Cogliano V., A review of human carcinogens? Part B: Biological agents, Lancet Oncol, 10, 4, pp. 321-2, (2009)

[4]

Monographs I., Human Papillomaviruses, IARC Monographs on the Evaluation of Carcinogenic Risks to Human, 64

[5]

Cogliano V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., Carcinogenicity of human papillomaviruses, Lancet Oncol, 6, 4, (2005)

[6]

Schiffman M., Herrero R., Desalle R., Hildesheim A., Wacholder S., Rodriguez A.C., Bratti M.C., Sherman M.E., Morales J., Guillen D., Alfaro M., Hutchinson M., Wright T.C., Solomon D., Chen Z., Schussler J., Castle P.E., Burk R.D., The carcinogenicity of human papillomavirus types reflects viral evolution, Virology, 337, 1, pp. 76-84, (2005)

[7]

Bosch F.X., Burchell A.N., Schiffman M., Giuliano A.R., De Sanjose S., Bruni L., Tortolero-Luna G., Kjaer S.K., Muoz N., Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia, Vaccine, 26, SUPPL 10, pp. 1-16, (2008)

[8]

Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., Clifford G.M., Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update, Int J Cancer, 121, 3, pp. 621-32, (2007)

[9]

Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., Rush B.B., Glass A.G., Schiffman M., The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16, or 18, and the possible utility of type-specific HPV testing in clinical practice, J Natl Cancer Inst, 97, 14, pp. 1072-9, (2005)

[10]

Sankaranarayanan R., Nene B.M., Shastri S.S., Jayant K., Muwonge R., Budukh A.M., Hingmire S., Malvi S.G., Thorat R., Kothari A., Chinoy R., Kelkar R., Kane S., Desai S., Keskar V.R., Rajeshwarkar R., Panse N., Dinshaw K.A., HPV screening for cervical cancer in rural India, N Engl J Med, 360, 14, pp. 1385-94, (2009)

← 1 2 3 →